| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
|
Azambuja, Evandro de
|
|
2009
|
4 |
2 |
p. 77-88
|
article
|
| 2 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors
|
Snider, Kelly L.
|
|
2009
|
4 |
2 |
p. 67-76
|
article
|
| 3 |
Indexing: the north face
|
Morère, Jean-François
|
|
2009
|
4 |
2 |
p. 63
|
article
|
| 4 |
Maximum tolerated dose: clinical endpoint for a bygone era?
|
Takimoto, Chris H.
|
|
2009
|
4 |
2 |
p. 143-147
|
article
|
| 5 |
QT interval prolongation among patients treated with angiogenesis inhibitors
|
Ederhy, Stephane
|
|
2009
|
4 |
2 |
p. 89-97
|
article
|
| 6 |
Renal toxicity of targeted therapies
|
Kelly, Ronan J.
|
|
2009
|
4 |
2 |
p. 121-133
|
article
|
| 7 |
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
|
Kelly, Kevin
|
|
2009
|
4 |
2 |
p. 99-105
|
article
|
| 8 |
Skin toxicities associated with epidermal growth factor receptor inhibitors
|
Li, Tianhong
|
|
2009
|
4 |
2 |
p. 107-119
|
article
|
| 9 |
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents
|
Sankhala, Kamalesh
|
|
2009
|
4 |
2 |
p. 135-142
|
article
|
| 10 |
The toxicities of modern targeted therapies—learning from the price of progress
|
Giles, Francis J.
|
|
2009
|
4 |
2 |
p. 65-66
|
article
|
Journal description